Vimta Labs Ltd
VIMTALABSVimta Labs Ltd is strength at full price. The numbers are improving — and a P/E at the 92nd percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 92nd percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (3 weeks in) while the P/E sits at the 92nd percentile of its own 6-year range. Underneath, the last four quarters read improving — profit +120.0% year on year, and 160% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Vimta Labs Ltd trades at ₹609, in a confirmed uptrend and 3 weeks into that stage. That is +15.0% against its own 200-day average. It sits at 44% of a 52-week range of ₹401 to ₹877. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 18 straight weeks.
Today the stock is in a confirmed uptrend — week 3 of stage 2, confirmed. At ₹609 it trades +15.0% versus its 200-day average and sits at 44% of its 52-week range (₹401–₹877).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +1,633% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 18 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Vimta Labs Ltd trades at 44.8× P/E, at the pricey end of its own range (92nd percentile). Its long-run median P/E is 26.2×, measured across 6.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 44.8× is at the pricey end of its own range (92nd percentile), against a long-run median of 26.2× measured over 6.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −14.8% against a −11.6% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +30.3%/yr price move, ~+14.0%/yr came from earnings growth and ~+16.3 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources disagree by up to 64% on reported income across 13 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Vimta Labs Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 8 quarters ago at −16.7% and has held its recovery at +120.0% (single-quarter readings), ROCE holding at 18.0%. The read is built from 9 quarters across 3 curves, on partial evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +0.0% | +14.7% | — | — |
| Profit | −14.6% | +25.0% | — | — |
| EPS | −14.8% | +24.1% | — | — |
| Share price | −11.6% | +34.9% | +30.3% | +30.0% |
4-Factor Sector Score
44.4/100 — rank 9 of 9 in Diagnostics · 45% evidence confidence · provisional, ranked below fully-evidenced peers
Vimta Labs Ltd scores 44.4 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 9. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 17.5 + 13.5 + 7.5 + 5.9 = 44.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Vimta Labs Ltd reported ₹90.0 Cr of revenue in the Dec 24 quarter, +20.0% year on year. That is the 2nd straight quarter of year-on-year growth. Over 4 years it has compounded at 15.1% a year. The last full year, FY24, came in at ₹318 Cr. The last four reported quarters add to ₹330 Cr.
FY24 revenue came in at ₹318 Cr (+0.0% on the year), capping 4 years at 15.1% compound. The latest quarter (Dec 24) printed ₹90.0 Cr, +20.0% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +9.2% growth against the decade's 15.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +7.8% over the last 4 quarters against +3.2%/yr over the last 8 — accelerating; TTM profit +48.8% vs +13.9%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Vimta Labs Ltd's operating margin is 37.0% in the Dec 24 quarter, +5.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 17.0% to 30.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 37.0%, +5.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 17.0%–30.0%.
Why the margin moved: operating margin went +4.7 pp year on year while gross margin went −2.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Vimta Labs Ltd earned ₹22.0 Cr of net profit in the Dec 24 quarter, +120.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY24 profit was ₹41.0 Cr. The 4-year compound rate is 55.6%. That is 24.4% of the quarter's revenue. The same quarter a year earlier earned ₹10.0 Cr.
Dec 24 profit was ₹22.0 Cr, +120.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY24 printed ₹41.0 Cr (−14.6%), and the 4-year compound rate is 55.6%.
Why profit moved: revenue contributed +20.0% and the margin +5.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +65.6% vs revenue +9.2%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 160% of Vimta Labs Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY24 that was ₹61.0 Cr of operating cash against ₹41.0 Cr of profit. After ₹77.0 Cr of capital spending, ₹−16.0 Cr was left as free cash.
FY24: operating cash of ₹61.0 Cr against reported profit of ₹41.0 Cr, leaving free cash of ₹−16.0 Cr after ₹77.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 160% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 160%: the cash cycle stretched 32 days between FY20 and FY24 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Vimta Labs Ltd's cash conversion cycle runs 223 days in FY24, up from 191 days in FY20. Capital spending ran ₹166 Cr over the last 3 years. At FY24 sales of ₹318 Cr each day of that cycle holds about ₹0.9 Cr, so roughly ₹194 Cr sits inside the business at any moment.
FY24: debtors at 100 days, inventory at 185 days — roughly 6.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 223 days, looser than FY20's 191.
The full loop: cash goes out to suppliers and production on day 0; stock waits 185 days to sell; customers pay about 100 days after that; and suppliers themselves are paid at 62 days — netting out to the 223-day cycle.
In money terms: at FY24 sales of ₹318 Cr, each day of the cycle holds about ₹0.9 Cr — so the 223-day loop keeps roughly ₹194 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹166 Cr over the last 3 fiscal years against ₹88.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹59.0 Cr (FY24) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Vimta Labs Ltd earns a ROCE of 18% in FY24. That is up from a trough of 14% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 12.9% net margin on 0.80× asset turns.
FY24 ROCE is 18%, recovered from a FY21 trough of 14% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY24): 12.9% net margin × 0.80× asset turns × 1.25× balance-sheet leverage ≈ 12.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 64% on reported income across 13 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Vimta Labs Ltd carries ₹19.0 Cr of borrowings against ₹319 Cr of equity in FY24, a debt-to-equity of 0.06. Operating profit covers the interest bill 44×. Over 4 years borrowings went from ₹33.0 Cr to ₹19.0 Cr. Capital spending ran ₹166 Cr across the last 3 of those years.
FY24: borrowings of ₹19.0 Cr against equity of ₹319 Cr — a debt-to-equity of 0.06. Operating profit covers the interest bill 44×. Over 4 years borrowings went from ₹33.0 Cr to ₹19.0 Cr while capital spending ran ₹166 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 64% on reported income across 13 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 1.2 points of Vimta Labs Ltd over 8 quarters, the biggest move on the register. That takes promoters to 35.7% of the company. Domestic institutions moved −1.1 points over the same window, to 0.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −1.2 points over 8 quarters to 35.7%; Domestic institutions: −1.1 points over 8 quarters to 0.4%; Foreign institutions: −0.8 points over 8 quarters to 4.4%.
🚨 Why the register moved: promoters drove it (−1.2 points), alongside domestic institutions (−1.1 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Vimta Labs Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Thyrocare Technologies LtdTHYROCARE | 77.4/100Favorable setup100% evidence | LEADER | 27.9/35 Revenue 21.3% · PAT 67.6% · OPM change 2 pp 100% evidence | 18.1/25 ROCE 35.4% · OPM 32% 100% evidence | 12.0/20 P/E 51× · PEG 1.1 100% evidence | 19.4/20 RS sector 16.8% · RS bench 27.8% · 1Y 32.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.9 + 18.1 + 12 + 19.4 = 77.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Dr Lal Pathlabs LtdLALPATHLAB | 63.3/100Mixed-positive evidence100% evidence | LEADER | 14.6/35 Revenue 14.3% · PAT 5% · OPM change 2 pp 100% evidence | 16.8/25 ROCE 28% · OPM 31% 100% evidence | 13.0/20 P/E 56.8× · PEG 1.29 100% evidence | 18.9/20 RS sector 11.6% · RS bench 22.5% · 1Y 23.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 16.8 + 13 + 18.9 = 63.3 · Decision use: Price leads the evidence: RS versus the benchmark is 22.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 3Metropolis Healthcare LtdMETROPOLIS | 60.1/100Mixed-positive evidence96% evidence | LEADER | 27.2/35 Revenue 23.7% · PAT 31.7% · OPM change 7 pp 88% evidence | 11.7/25 ROCE 17.8% · OPM 25% 100% evidence | 6.3/20 P/E 62.3× · PEG 2.4 100% evidence | 14.9/20 RS sector 4.3% · RS bench 14.4% · 1Y 18.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 11.7 + 6.3 + 14.9 = 60.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4One Global Service Provider Ltd514330 | 59.8/100Mixed-positive evidence78% evidence | TURNING | 24.9/35 Revenue 100% · PAT 100% · OPM change -8 pp 83% evidence | 16.5/25 ROCE 87% · OPM 18% 76% evidence | 10.1/20 P/E 15.9× · PEG — 50% evidence | 8.3/20 RS sector 1.3% · RS bench 10.9% · 1Y 121.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 16.5 + 10.1 + 8.3 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Vijaya Diagnostic Centre LtdVIJAYA | 58.8/100Mixed-positive evidence96% evidence | LEADER | 20.1/35 Revenue 19.5% · PAT 20.1% · OPM change 4 pp 88% evidence | 18.5/25 ROCE 21.3% · OPM 44% 100% evidence | 6.4/20 P/E 80× · PEG 1.46 100% evidence | 13.8/20 RS sector 11.3% · RS bench 21.8% · 1Y 25.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 18.5 + 6.4 + 13.8 = 58.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 63B Blackbio DX Ltd3BBLACKBIO | 48.6/100Mixed-negative evidence83% evidence | TURNING | 15.2/35 Revenue 47.1% · PAT 25.7% · OPM change -11.2 pp 83% evidence | 15.8/25 ROCE 25.5% · OPM 24% 95% evidence | 11.8/20 P/E 18.3× · PEG — 50% evidence | 5.8/20 RS sector -17.6% · RS bench -9.3% · 1Y -13.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 15.8 + 11.8 + 5.8 = 48.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Krsnaa Diagnostics LtdKRSNAA | 43.0/100Mixed-negative evidence77% evidence | ASLEEP | 13.4/35 Revenue 7.8% · PAT 30.8% · OPM change 0 pp 83% evidence | 10.5/25 ROCE 12.7% · OPM 28% 95% evidence | 14.6/20 P/E 16.9× · PEG — 50% evidence | 4.5/20 RS sector -18.5% · RS bench -23.4% · 1Y -38.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13.4 + 10.5 + 14.6 + 4.5 = 43 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Suraksha Diagnostic LtdSURAKSHA | 39.0/100Mixed-negative evidence76% evidence | ASLEEP | 13.8/35 Revenue 23.1% · PAT 1.4% · OPM change 0.5 pp 83% evidence | 13.0/25 ROCE 17% · OPM 29.9% 95% evidence | 10.4/20 P/E 40.8× · PEG — 15% evidence | 1.8/20 RS sector -20.4% · RS bench -12.3% · 1Y -17.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 13 + 10.4 + 1.8 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Vimta Labs Ltdthis pageVIMTALABS | 44.4/100Thin evidence · provisional45% evidence | TURNING | 17.5/35 Revenue 7.8% · PAT 48.8% · OPM change 5 pp 18% evidence | 13.5/25 ROCE 17.6% · OPM 37% 57% evidence | 7.5/20 P/E 44.8× · PEG — 50% evidence | 5.9/20 RS sector -21.9% · RS bench 4.8% · 1Y 4.1%7 of 10 weeks ahead 70% evidence |
| Exact sum: 17.5 + 13.5 + 7.5 + 5.9 = 44.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Vimta Labs Ltd's share price today?
Vimta Labs Ltd trades at ₹609, −11.6% over the past year. The company is valued at ₹2,721 Cr. The stock sits at 44% of its 52-week range of ₹401–₹877, +15.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 3 weeks in. — as of 31 July 2026.
What were Vimta Labs Ltd's latest quarterly results?
Vimta Labs Ltd reported revenue of ₹90.0 Cr and net profit of ₹22.0 Cr for the Dec 24 quarter. Revenue rose 20.0% and profit rose 120.0% year on year. Earnings per share were ₹4.84. The operating margin was 37.0%, 5.0 pp higher than a year earlier. — as of 31 July 2026.
What is Vimta Labs Ltd's revenue?
Vimta Labs Ltd reported revenue of ₹90.0 Cr in the Dec 24 quarter, +20.0% year on year. For the full FY24 fiscal year, revenue was ₹318 Cr (+0.0%). Over the last 4 years revenue compounded at 15.1% a year. — as of 31 July 2026.
What is Vimta Labs Ltd's profit?
Vimta Labs Ltd earned ₹22.0 Cr of net profit in the Dec 24 quarter, +120.0% year on year — the 2nd straight quarter of growth. Full-year FY24 profit was ₹41.0 Cr. The operating margin ran 37.0% in the latest quarter. — as of 31 July 2026.
What is Vimta Labs Ltd's market cap?
Vimta Labs Ltd's market capitalisation is ₹2,721 Cr at a share price of ₹609. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Vimta Labs Ltd's P/E ratio?
Vimta Labs Ltd trades at a P/E of 44.8×, at the 92nd percentile of its own 6-year range, against a long-run median of 26.2×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Vimta Labs Ltd pay a dividend?
Yes — Vimta Labs Ltd's dividend payout was 11% of profit in FY24, and it recorded a payout in 4 of its last 5 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Vimta Labs Ltd overvalued?
On its own history, Vimta Labs Ltd looks expensive against its own history: its P/E of 44.8× sits at the 92nd percentile of its 6-year range (long-run median 26.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Vimta Labs Ltd growing?
Yes — Vimta Labs Ltd is growing: latest-quarter revenue +20.0% year on year, profit +120.0%, and the margin +5.0 pp at 37.0%. The 4-year compound rates are 15.1% (revenue) and 55.6% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Vimta Labs Ltd performing?
Vimta Labs Ltd is in a confirmed uptrend, 3 weeks in. Its latest quarter's revenue rose 20.0% and profit rose 120.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 18 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Vimta Labs Ltd in?
Improving — profit growth bottomed 8 quarters ago at −16.7% and has held its recovery at +120.0% (single-quarter readings), ROCE holding at 18.0%. The read comes from the last 12 quarters of growth (revenue growth +20.0% latest, profit growth +120.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Vimta Labs Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 3 of stage 2), trading +15.0% versus its 200-day average and at 44% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Vimta Labs Ltd beating the market?
On recent form, yes — Vimta Labs Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 18 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +1,633% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Vimta Labs Ltd's share price go up?
This page publishes no price forecast for Vimta Labs Ltd. What it measures instead: the share price is ₹609, the price is in a confirmed uptrend 3 weeks in. Its P/E of 44.8× sits at the 92nd percentile of its own 6-year range. — as of 31 July 2026.
Who owns Vimta Labs Ltd?
Promoters hold 35.7% of Vimta Labs Ltd, foreign institutions 4.4%, domestic institutions 0.4% and the public 59.5% (latest quarter). The biggest move on the register over the last two years: Promoters cut 1.2 points over 8 quarters. — as of 31 July 2026.
Does Vimta Labs Ltd have too much debt?
No — Vimta Labs Ltd's debt-to-equity is 0.06, and operating profit covers the interest bill 44×. FY24 borrowings were ₹19.0 Cr against equity of ₹319 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Vimta Labs Ltd's capex?
Vimta Labs Ltd spent ₹166 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY24 alone that was ₹77.0 Cr, with ₹59.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Vimta Labs Ltd's cash flow?
Vimta Labs Ltd generated ₹61.0 Cr of operating cash flow in FY24 and ₹−16.0 Cr of free cash flow after ₹77.0 Cr of capital spending. Reported profit that year was ₹41.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Vimta Labs Ltd's profit real cash?
Yes — over the last 3 fiscal years, 160% of Vimta Labs Ltd's reported profit arrived as operating cash. In FY24, operating cash was ₹61.0 Cr against reported profit of ₹41.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Vimta Labs Ltd in its business cycle?
Vimta Labs Ltd's FY24 operating margin was 27.0%, against a 5-year band of 17.0%–30.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 37.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Vimta Labs Ltd story?
The sharpest disagreement: the engine is strong, but at the 92nd percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Vimta Labs Ltd a stock worth studying right now?
This is not investment advice. The machine read: Vimta Labs Ltd is strength at full price. The numbers are improving — and a P/E at the 92nd percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.